Literature DB >> 23686690

Laboratory tests during direct oral anticoagulant treatment? Yes.

Vittorio Pengo1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23686690     DOI： 10.1007/s11739-013-0949-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  10 in total

Review 1.  New anticoagulants.

Authors:  John W Eikelboom; Jeffrey I Weitz
Journal:  Circulation       Date:  2010-04-06       Impact factor: 29.690

2.  VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.

Authors:  Carlo-Federico Zambon; Vittorio Pengo; Roberto Padrini; Daniela Basso; Stefania Schiavon; Paola Fogar; Alessandra Nisi; Anna Chiara Frigo; Stefania Moz; Michela Pelloso; Mario Plebani
Journal:  Pharmacogenomics       Date:  2011-01       Impact factor: 2.533

3.  Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.

Authors:  J Kooiman; W R van de Peppel; F J M van der Meer; M V Huisman
Journal:  J Thromb Haemost       Date:  2011-08       Impact factor: 5.824

Review 4.  Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

Authors:  V Pengo; L Crippa; A Falanga; G Finazzi; F Marongiu; G Palareti; D Poli; S Testa; E Tiraferri; A Tosetto; A Tripodi; C Manotti
Journal:  Thromb Haemost       Date:  2011-09-22       Impact factor: 5.249

Review 5.  Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.

Authors:  V Pengo; L Crippa; A Falanga; G Finazzi; F Marongiu; M Moia; G Palareti; D Poli; S Testa; E Tiraferri; A Tosetto; A Tripodi; S Siragusa; C Manotti
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

Review 6.  Clinical management of rivaroxaban-treated patients.

Authors:  Gualtiero Palareti; Walter Ageno; Annamaria Ferrari; Alessandro Filippi; Davide Imberti; Vittorio Pengo; Andrea Rubboli; Danilo Toni
Journal:  Expert Opin Pharmacother       Date:  2013-02-17       Impact factor: 3.889

7.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

8.  Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

Authors:  Michael D Ezekowitz; Paul A Reilly; Gerhard Nehmiz; Timothy A Simmers; Rangadham Nagarakanti; Kambiz Parcham-Azad; K Erik Pedersen; Dominick A Lionetti; Joachim Stangier; Lars Wallentin
Journal:  Am J Cardiol       Date:  2007-08-17       Impact factor: 2.778

9.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

Authors:  Maria Gabriella Scordo; Vittorio Pengo; Edoardo Spina; Marja Liisa Dahl; Milena Gusella; Roberto Padrini
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

10.  Worldwide management of oral anticoagulant therapy: the ISAM study.

Authors:  Vittorio Pengo; Cinzia Pegoraro; Umberto Cucchini; Sabino Iliceto
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300
  10 in total
  6 in total

1.  Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills.

Authors:  Francesco Marongiu; Doris Barcellona
Journal:  Intern Emerg Med       Date:  2013-12-25       Impact factor: 3.397

Review 2.  The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

Authors:  Armando Tripodi; Francesco Marongiu; Marco Moia; Gualtiero Palareti; Vittorio Pengo; Daniela Poli; Domenico Prisco; Sophie Testa; Maria Zanazzi
Journal:  Intern Emerg Med       Date:  2018-04-26       Impact factor: 3.397

Review 3.  Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants.

Authors:  Stefano Sivolella; Marleen De Biagi; Giulia Brunello; Mario Berengo; Vittorio Pengo
Journal:  Odontology       Date:  2015-02-06       Impact factor: 2.634

4.  Laboratory tests during direct oral anticoagulant treatment?

Authors:  Alberto Tosetto
Journal:  Intern Emerg Med       Date:  2014-08-12       Impact factor: 3.397

5.  Laboratory tests during direct oral anticoagulant treatment.

Authors:  Armando Tripodi; Simon Braham; Marco Moia
Journal:  Intern Emerg Med       Date:  2014-02-04       Impact factor: 3.397

6.  Laboratory tests during direct oral anticoagulant treatment.

Authors:  Sophie Testa; Oriana Paoletti
Journal:  Intern Emerg Med       Date:  2014-01-14       Impact factor: 3.397
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.